Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients

dc.contributor.authorAshcheulova, Tetyana
dc.contributor.authorGerasimchuk, Nina
dc.contributor.authorKovalyova, Olga
dc.contributor.authorHonchar, Oleksii
dc.date.accessioned2018-11-12T08:33:26Z
dc.date.available2018-11-12T08:33:26Z
dc.date.issued2018-11
dc.description.abstractIntroduction Obesity is becoming one of the leading risk factors of coronary heart disease, hypertension, cerebrovascular disease. Despite the presence of a large number of antihypertensive agents and scientific substantiation of antihypertensive treatment principles it would be wrong to assume that the problem is completely solved. Development of endothelial dysfunction is one of the key pathogenic mechanisms in hypertension. This process is proven to be contributed by immune inflammation activation which is mediated by pro-inflammatory cytokines and oxidative stress. Aims: To investigate the additional benefits of the combined antihypertensive therapy with lacidipine and candesartan on the basis of studying their antioxidant properties, impact on endothelial function and pro-inflammatory cytokines activity in hypertensive patients with overweight and obesity. Methods A combination of a calcium channel blocker and angiotensin receptor blocker (lacidipine 2 mg, 4 mg, and candesartan 4mg, 8mg, 16mg) was prescribed to 30 patients with essential hypertension of grades 1-3, 30 to 65 years old (mean age – 54.7 ± 5.8 years), who previously have not been receiving regular antihypertensive therapy. Results During the course of combined antihypertensive therapy with lacidipine and candesartan, a significant reduction in i-NOS activity, TNF-α to its type I soluble receptor ratio (TNF-α/sTNF-αRI), and oxidative stress marker – 8-iso-PgF2α has been observed. Activity of e- NOS, levels of SOD and catalase, in contrast, have increased by the end of observation period. Conclusion The improvement of endothelial function due to lower level of oxidative stress and a significant decrease of immune activation has been observed in hypertensive patients with overweight and obesity under the influence of combined antihypertensive therapy with lacidipine and candesartan.ru_RU
dc.identifier.citationBeneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients / T. Ashcheulova, N. Gerasimchuk, O. Kovalyova, O. Honchar // Romanian Journal of Internal Medicine. – 2018. – 56 (4). – DOI: https://doi.org/10.2478/rjim-2018-0018.ru_RU
dc.identifier.urihttps://repo.knmu.edu.ua/handle/123456789/20977
dc.language.isoenru_RU
dc.subjecthypertensionru_RU
dc.subjectobesityru_RU
dc.subjectoxidative stressru_RU
dc.subjectnitric oxide synthaseru_RU
dc.subjecttumor necrosis factor-α,ru_RU
dc.subjectcatalaseru_RU
dc.subjectlacidipineru_RU
dc.subjectcandesartanru_RU
dc.titleBeneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patientsru_RU
dc.typeArticleru_RU

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
[2501062X - Romanian Journal of Internal Medicine] Beneficial effects of combined therapy with lacidipine and candesartan in obese hypertensive patients.pdf
Size:
404.61 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
11.51 KB
Format:
Item-specific license agreed upon to submission
Description: